Core Viewpoint - Eli Lilly and Co has issued a warning regarding safety risks associated with compounded tirzepatide products mixed with vitamin B12, highlighting the discovery of an impurity formed from this combination [1][2][3]. Group 1: Safety Concerns - Internal testing revealed significant levels of an impurity created through a chemical reaction between tirzepatide and vitamin B12 [2]. - The newly identified impurity raises concerns due to unknown health effects in humans, with no data on its influence on tirzepatide's interaction with GLP-1 and GIP receptors, potential toxicity, immune response, and pharmacokinetics [3]. - Compounded versions of tirzepatide are not subject to the same adverse event tracking as FDA-approved medicines, increasing the risk for patients [4]. Group 2: Regulatory and Market Issues - The company expressed concerns about mass-compounded versions of its tirzepatide medicines, Mounjaro and Zepbound, and supports FDA actions to limit the distribution of compounded anti-obesity drugs that may violate regulatory standards [5]. - Lilly criticized the marketing of "personalized" versions of tirzepatide by compounding pharmacies, which often use identical additives in bulk-produced products rather than customizing for individual patients [6]. Group 3: Additional Risks - Beyond vitamin B12, compounded tirzepatide products have been mixed with other substances such as glycine, pyridoxine, niacinamide, and carnitine, which have not undergone clinical testing [7]. - The company has identified other potential safety issues in compounded tirzepatide products, including bacterial contamination, elevated endotoxin levels, and additional impurities not found in its FDA-approved medicines [7]. - Lilly has encouraged the FDA to consider recalls of compounded tirzepatide products containing untested additives like vitamin B12 [8].

Core Viewpoint - Eli Lilly & Co. has raised concerns about the safety of its weight-loss drug Zepbound when combined with vitamin B12, highlighting potential risks from impurities found in compounded products [1][2] Group 1: Safety Concerns - The company discovered significant levels of an impurity resulting from a chemical reaction between tirzepatide and vitamin B12 in compounded products [1] - Lilly warned that patients using tirzepatide-B12 combinations from various sources may face unknown risks, including potential toxicity and immune reactions [2] - Testing revealed other critical safety issues, such as bacterial contamination and high levels of endotoxin, a toxic component [4] Group 2: Regulatory Context - Compounded medicines were initially allowed in the US due to a supply shortage during the early weight-loss injection boom, but the FDA has since declared the shortage over [3] - Despite the FDA's ruling, compounders continue to sell their products by exploiting regulatory loopholes, allowing them to customize drug formulations [3] - Lilly has urged the FDA to recall all compounded versions of its medicine that include untested additives [4] Group 3: Competitive Landscape - Eli Lilly faces competition from cheaper knock-off versions of its obesity and diabetes treatments, which bypass the rigorous regulatory approval process required for brand-name or generic drugs [2]

Eli Lilly warned that the active ingredient in Zepbound could pose a risk to patients when mixed with vitamin B12 https://t.co/2LecIXDQuu ...